The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Open accessAbstract
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8⁺ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8⁺ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8⁺ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8⁺ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8⁺ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβ deep sequencing revealed oligoclonal expansion of specific TCRβ clonotypes in CD8⁺PD-1⁺ compared with CD8⁺PD-1- TIL populations. Furthermore, the most highly expanded TCRβ clonotypes in the CD8⁺ and the CD8⁺PD-1⁺ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8⁺ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“We measured cell surface expression of differentiation markers CD62L, CD45RO, CD27, and CD57 (31), inhibitory receptors PD-1, LAG-3, TIM-3, and BTLA, typically expressed on chronically stimulated CD8+ T cells (23, 24, 32, 33), and costimulatory receptor 4-1BB (28, 34) and IL-2 receptor alpha CD25 (35), which can be up…”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citation
Cited by
Items 101–117 of 117
(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
Self-citationAcquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186
“As a consequence, PD-1 is a marker of tumor-associated antigen (TAA)-specific tumor-infiltrating lymphocytes (TILs) (9).”
BackgroundSeifert, A. M., Zeng, S., Zhang, J. Q., Kim, T. S., Cohen, N. A., Beckman, M. J., Medina, B. D., Maltbaek, J. H., Loo, J. K., Crawley, M. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1163 · Cited by 149
Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
Liu, Z., Li, J. P., Chen, M., Wu, M., Shi, Y., Li, W., Teijaro, J. R., & Wu, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.048 · Cited by 148
“Although the PD-1+Bio+ TIL subset was found to express higher levels of TIM-3 and CD137 than the PD-1+Bio− TILs, varying levels of LAG-3, CD39, and CD103 expression were found in both subsets (Duhen et al., 2018; Gros et al., 2014; Yossef et al., 2018).”
BackgroundOja, A. E., Piet, B., van der Zwan, D., Blaauwgeers, H., Mensink, M., de Kivit, S., Borst, J., Nolte, M. A., van Lier, R. A. W., Stark, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02654 · Cited by 130
“Paradoxically, PD-1 expression has also been described as a favorable prognostic marker in several cancers, in which it defines tumor-specific CD8 T cells (34, 35).”
BackgroundKohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0759 · Cited by 126
PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation
Petrelli, A., Mijnheer, G., van Konijnenburg, D. P. H., van der Wal, M. M., Giovannone, B., Mocholi, E., Vazirpanah, N., Broen, J. C., Hijnen, D., Oldenburg, B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96107 · Cited by 126
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114
Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2209 · Cited by 88
Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59
Breaking Bottlenecks for the TCR Therapy of Cancer
Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52
Breast Cancer and the Other Non-Coding RNAs
Dvorská, D., Braný, D., Ňachajová, M., Halašová, E., & Danková, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063280 · Cited by 38
Sekido, K., Tomihara, K., Tachinami, H., Heshiki, W., Sakurai, K., Moniruzzaman, R., Imaue, S., Fujiwara, K., & Noguchi, M. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104462 · Cited by 23
Metadata
- Authors
- Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., Hanada, K.-I., Almeida, J. R., Darko, S., Douek, D. C., Yang, J. C., & Rosenberg, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-03-25
- Volume
- 124
- Issue
- 5
- Pages
- 2246-2259
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1980137951
- Cited by
- 1,111
- References
- 71
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.